An analyst apologized to clients late Wednesday for his calls on troubled biotechnology company Dendreon Corp., as he moved his rating on the shares to hold from buy in the wake of the company lowering sales estimates for the coming …
Many investors appear to be quite bearish on Dendreon Corporation (DNDN), especially if you look at the percentage of the float that is sold short for this stock. Currently, 26.96% of the float is sold short, suggesting an extreme level of …
Friday it will pay for a greater number of patients to receive Provenge, a prostate cancer drug made by Dendreon Corp, sending Dendreon's shares up as much as 10 percent.
Providing that sometimes requires additional lengthy and expensive clinical trials. Although the near-term impact on Dendreon’s stock was severe — its shares plunged by 60 percent on the news — chances are good that Provenge or …
Despite Tuesday's sharp decline, Dendreon's shares have gained 0.89% in the last five trading sessions and 11.60% in …
Dendreon's stock price took a hit, as investors tried to second-guess which way the winds were blowing at the agency. But as the previous panel had voted for approval with clinical data that fell short of statistical significance, it seemed …
Dendreon expects to seek a six-month expedited review by the Food and Drug Administration and to have the drug on the market in 2005, Mitchell Gold, Dendreon's chief executive, said. Stock in Dendreon, which is based in Seattle, rose …
Since 2011, Dendreon has changed chief executives twice and reduced its staff to about 700, about half the peak level. It still lost $22 million in the most recent quarter. The company’s stock was down about 70 percent, at about 30 cents a …